NCT06532331View on ClinicalTrials.gov

A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

December 6, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

March 31, 2028

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

ONO-7475

Specified dose on specified days

DRUG

ONO-4538

Specified dose on specified days

DRUG

Nab-paclitaxel

Specified dose on specified days

DRUG

Gemcitabine

Specified dose on specified days

Trial Locations (9)

Unknown

Aichi Cancer Center, Nagoya

National Cancer Center Hospital East, Kashiwa-shi

Kanazawa University Hospital, Kanazawa

Kanagawa Cancer Center, Yokohama

Osaka International Cancer Institute, Osaka

Seirei Hamamatsu General Hospital, Hamamatsu

Juntendo University Hpspital, Bunkyo-ku

The University of Tokyo Hospital, Bunkyo-ku

The Cancer Institute Hospital Of JFCR, Koto-Ku

Sponsors
All Listed Sponsors
lead

Ono Pharmaceutical Co. Ltd

INDUSTRY

NCT06532331 - A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer | Biotech Hunter | Biotech Hunter